KORIAN (KORI.PA)       9.01  -0.58 (-6.05%)

9.01  -0.58 (-6.05%)

FR0010386334 - Common Stock


Fundamental Rating

3

Overall KORI gets a fundamental rating of 3 out of 10. We evaluated KORI against 10 industry peers in the Health Care Providers & Services industry. KORI has a bad profitability rating. Also its financial health evaluation is rather negative. KORI has a correct valuation and a medium growth rate.




Profitability

Profitability Rating

2

The Piotroski-F score of KORI is 7.00. This is a strong score and indicates good health and profitability for KORI.
KORI's Return On Assets of 0.53% is worse than the rest of the industry. The industry average Return On Assets is 2.27%. 89% of the industry peers have a better Return On Assets.

KORI has a Return On Equity of 2.17%. This is below the industry average of 7.56%. 89% of the industry peers outperform KORI.
KORI has a Profit Margin of 1.75%. This is below the industry average of 3.64%.
VS Industry

ROA (0.53%) VS Industry: 11% outperformed.

0.33
7.24

ROE (2.17%) VS Industry: 11% outperformed.

1.76
18.67

Profit Margin (1.75%) VS Industry: 22% outperformed.

0.85
11.09

Valuation

Valuation Rating

6

The Price/Earnings Ratio is 10.60, which indicates a very decent valuation of KORI.
KORI's Price/Earning Ratio is a bit cheaper than the industry average which is at 11.87.
With a Forward Price/Earnings Ratio of 6.68, the valuation of KORI can be described as cheap.

With a price book ratio of 0.28, KORI is valued rather cheaply.
Compared to an average industry price book ratio of 1.17, KORI is valued rather cheaply. On top of this, KORI is cheaper than 88% of the companies listed in the same industry.
When comparing the Enterprise Value to EBITDA ratio of KORI to the average industry ratio of 7.90, KORI is valued more expensive than its industry peers.
VS Industry

Price/Earnings (10.6) VS Industry: 66% outperformed.

32.44
2.75

Price/Book (0.28) VS Industry: 88% outperformed.

3.91
0.05

Enterprise Value/ EBITDA (8.61) VS Industry: 37% outperformed.

13.91
3.26

Growth

Growth Rating

5

KORI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 96.86%, which is quite impressive.
Based on estimates for the next 5 years, KORI will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.26% on average per year.
The EPS growth is accelerating: in the next 5 years the growth will be better than in the last years.
Measured over the past 5 years, KORI shows a decrease in Earnings Per Share. The EPS has been decreasing by -8.00% on average per year.

The Revenue has been growing slightly by 9.42% in the past year.
KORI shows a small growth in Revenue. Measured over the last 5 years, the Revenue has been growing by 6.86% yearly.
Based on estimates for the next 5 years, KORI will show a small growth in Revenue. The Revenue will grow by 5.92% on average per year.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is stable.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPS-8% -8.21% 96.86% -1.54% 11.58% 11.44% 14.26%
Revenue6.86% 7.6% 9.42% 7.41% 7.84% 7.36% 5.92%

Health

Health Rating

1

The Piotroski-F score of KORI is 7.00. This is a strong score and indicates good health and profitability for KORI.
A Current Ratio of 0.88 indicates that KORI may have some problems paying its short term obligations.
When comparing the Current Ratio of KORI to the average industry Current Ratio of 1.34, KORI is less able to pay its short term obligations than its industry peers.
KORI has a Quick Ratio of 0.88. This is a bad value and indicates that KORI is not financially healthy enough and could expect problems in meeting its short term obligations.

Compared to an average industry Quick Ratio of 0.97, KORI is worse placed to pay its short term obligations than its industry peers.
Compared to an average industry Debt to Equity Ratio of 1.09, KORI is requires more financing than its industry peers. 89% of its industry peers have a better Debt to Equity Ratio.
KORI has an Altman-Z score of 0.58. This is a bad value and indicates that KORI is not financially healthy and even has some risk of bankruptcy.
When comparing the Altman-Z score of KORI to the average industry Altman-Z score of 1.60, KORI is less financially healthy than its industry peers. 89% of its industry peers have a better Altman-Z score.
VS Industry

Debt/Equity (2.12) VS Industry: 11% outperformed.

2.94
0.04

Quick Ratio (0.86) VS Industry: 33% outperformed.

0.47
2.30

Current Ratio (0.88) VS Industry: 22% outperformed.

0.64
3.05

Altman-Z (0.58) VS Industry: 11% outperformed.

0.37
5.93

Dividend

Dividend Rating

4

KORI's Dividend Yield is a higher than the industry average which is at 3.25.
KORI's Dividend Yield is a higher than the S&P500 average which is at 2.41.
KORI has a Yearly Dividend Yield of 3.56%.

50.45% of the earnings are spent on dividend by KORI. This is a bit on the high side, but may be sustainable.
The dividend of KORI decreases each year by -14.20%.
VS Industry

Dividend Yield (3.56%) VS Industry: 80% outperformed.

1.02
3.99

KORIAN9.01

EPA:KORI (2/3/2023, 7:00:00 PM)-0.58 (-6.05%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Health Care Equipment & Services
GICS Industry Health Care Providers & Services
Earnings (Last) N/A N/A Earnings (Next) N/A N/A
Inst Owners N/A Inst Owner Change N/A
Ins Owners N/A Ins Owner Change N/A
Market Cap 959.18M Analysts 84
Price Target 24.74 (174.58%)

Dividend
Industry RankSector Rank
Dividend Yield 3.56%
Dividend Growth(5Y) -14.2% DP 50.45%
Div Incr Years N/A Div Non Decr Years N/A
Ex-Date N/A

Surprises & Revisions
EPS beat(2) N/A Avg EPS beat(2) N/A
Min EPS beat(2) N/A Max EPS beat(2) N/A
EPS beat(4) N/A Avg EPS beat(4) N/A
Min EPS beat(4) N/A Max EPS beat(4) N/A
Revenue beat(2) N/A Avg Revenue beat(2) N/A
Min Revenue beat(2) N/A Max Revenue beat(2) N/A
Revenue beat(4) N/A Avg Revenue beat(4) N/A
Min Revenue beat(4) N/A Max Revenue beat(4) N/A
PT rev (1m) -5.27% PT rev (3m) -11.33%
EPS NQ rev (1m) N/A EPS NQ rev (3m) N/A
EPS NY rev (1m) 0% EPS NY rev (3m) -5.8%
Revenue NQ rev (1m) N/A Revenue NQ rev (3m) N/A
Revenue NY rev (1m) 0% Revenue NY rev (3m) -0.02%

Valuation
Industry RankSector Rank
PE 10.6
Fwd PE 6.68
P/S 0.22
P/FCF 2.75
P/OCF 1.05
P/B 0.28
P/tB N/A
EV/EBITDA 8.61
EPS(TTM) 0.85 EY 9.43%
EPS(NY) 1.35 Fwd EY 14.97%
FCF(TTM) 3.28 FCFY 36.38%
OCF(TTM) 8.55 OCFY 94.91%
SpS 40.51 BVpS 32.7
TBVpS -18.24 PEG (NY) N/A
PEG (5Y) N/A

Profitability
Industry RankSector Rank
ROA 0.53%
ROE 2.17%
ROIC 2.25%
ROICexc 2.43%
ROICexgc 4.78%
OM 7.72%
PM 1.75%
GM 92.59%
ROICexgc(3y) 5.81% ROICexcg growth 3Y -30.77%
ROICexcg growth 5Y -20.62% ROICexc(3y) 2.8%
ROICexc growth 3Y -15.58% ROICexc growth 5Y -7.46%
OM growth 3Y -3.2% OM growth 5Y 0.58%
PM growth 3Y -14.88% PM growth 5Y -12.35%
GM growth 3Y 0.16% GM growth 5Y 0.09%
F-Score 7 Asset Turnover 0.3

Health
Industry RankSector Rank
Debt/Equity 2.12
Debt/FCF 23.4
Debt/EBITDA 8.36
Cap/Depr 87.16%
Profit Quality 462.86%
Current Ratio 0.88
Quick Ratio 0.86
Altman-Z 0.58
F-Score 7 WACC 3.28%
ROIC/WACC 1.46 Cap/Depr(3y) 85.49%
Cap/Depr(5y) 109.9% Profit Quality(3y) 471.28%
Profit Quality(5y) 325.13%

Growth
EPS 1Y 96.86% EPS 3Y -8.21%
EPS 5Y -8% EPS growth Q2Q -57.04%
EPS Next Y -1.54% EPS Next 2Y 11.58%
EPS Next 3Y 11.44% EPS Next 5Y 14.26%
Revenue growth 1Y 9.42% Revenue growth 3Y 7.6%
Revenue growth 5Y 6.86% Revenue growth Q2Q 7.92%
Revenue Next Year 7.41% Revenue Next 2Y 7.84%
Revenue Next 3Y 7.36% Revenue Next 5Y 5.92%
EBIT growth 1Y 11.54% EBIT growth 3Y 4.16%
EBIT growth 5Y 7.48% EBIT Next Year 185.81%
EBIT Next 3Y 49.6% EBIT Next 5Y 35.77%
FCF growth 1Y -55.73% FCF growth 3Y 40.91%
FCF growth 5Y 16.35% OCF growth 1Y 29.17%
OCF growth 3Y 31.29% OCF growth 5Y 22.67%

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the EuroNext

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the EuroNext

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the EuroNext

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the EuroNext